Cardiovascular Disease Connect
  • Saved

8mo
AHA Scientific Sessions 2025: Transformative advances in cardiovascular care

Dr. Joanna Chikwui, Chief of Cardiac Surgery at Cedars-Sinai and Chair of AHA Scientific Sessions, spotlighted significant breakthroughs across cardiology. Updates included novel therapies for hyperlipidemia, gene-editing tools for inherited cardiovascular risk, innovations in atrial fibrillation management, and compelling lifestyle findings—including a surprising inverse relationship between moderate coffee intake and AF incidence.

Dr. Heidi May, Epidemiologist at Intermountain Health, presented results from the Target-D randomized trial, which found that personalized vitamin D dosing after myocardial infarction significantly reduced the risk of recurrent heart attack. These findings underscore the importance of individualized supplementation strategies and signal a broader shift toward precision prevention and risk stratification in cardiovascular care.

Share your thoughts

  • Saved

8mo
Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis - PubMed

Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41261111/

Cardiovascular diseases and diabetes are associated with significant mortality, morbidity, and economic burden, highlighting the need for alternative preventive strategies. Honey bee products, including honey, royal jelly, and propolis, are...

Review of 69 RCTs shows honey has mixed metabolic effects, while royal jelly and propolis provide dose-dependent improvements in lipids, glycemic control, inflammation, and oxidative stress, supporting their potential cardiometabolic benefits with cautious honey use.

  • Saved

9mo
Optional or optimal? off-label stenting for intracranial atherosclerotic stenosis: A scoping review - PubMed

Optional or optimal? off-label stenting for intracranial atherosclerotic stenosis: A scoping review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37122266/

BackgroundIntracranial atherosclerotic stenosis is a major cause of ischemic stroke. In addition to the Wingspan stent system, several self-expanding stents have been used off-label to treat intracranial atherosclerotic stenosis lesions....

Off-label self-expanding stents for intracranial atherosclerotic stenosis show variable safety and feasibility, with limited evidence and heterogeneity, highlighting the need for lesion-specific selection and cautious, individualized clinical use.

  • Saved

9mo
Advances in lung health and sleep medicine: Key highlights from CHEST 2025

At CHEST 2025 in Chicago, pulmonology experts shared new insights in asthma, COPD, interstitial lung disease, pulmonary hypertension, and sleep medicine. Dr. Sandhya Khurana highlighted emerging asthma data—such as imaging-based reductions in mucus plugging and outcomes in severe asthma with nasal polyps—while also discussing the future of nanobody therapeutics. Dr. Cosmo Fowler reviewed GLP-1 RA–linked survival benefits in OSA.

Share your thoughts

  • Saved

9mo
infographic